InteRNA Genomics and Biotique Systems Offer SOLiD(TM) System Supported Software Solutions

FOSTER CITY, Calif., Jul 22, 2008 (BUSINESS WIRE) -- Applied Biosystems Inc. (NYSE:ABI) today announced the addition of
new members to its Software Development Community by forming
relationships with InteRNA Genomics B.V. and Biotique Systems, Inc.
The commercial software solutions offered by these companies are
intended to advance data analysis and management for researchers
utilizing Applied Biosystems' SOLiD(TM) System, the company's
ultra-high-throughput platform for DNA sequencing and genomic analysis
research.

The Applied Biosystems Software Development Community supports
bioinformaticians and life scientists in the development and potential
commercialization of informatics applications for next-generation
genomic analysis platforms. The community has noted approximately
1,000 downloads of sample data sets and data analysis tools and
resources by the hundreds of researchers, independent software
vendors, bioinformatics service providers, and SOLiD System users who
have visited the site.

Applied Biosystems Software Development Community is expected to
help drive innovation and speed the development of bioinformatics
solutions that will enable researchers to realize the full potential
of ultra-high- throughput genomic analysis.

InteRNA Genomics B.V., co-founded by Aglaia Biomedical Ventures
and pioneers in the application of high-throughput sequencing
technologies for expression profiling and the discovery of small RNAs
and microRNAs, is providing services for processing, analyzing and
presenting RNA sequencing data. Applied Biosystems also formed an
agreement with Biotique Systems, Inc., which provides a data
management solution for integrating, analyzing and sharing data
generated by next-generation sequencing platforms. Additional new
members to the Software Development Community are Genomatix Software
GmbH, and BioTeam.

InteRNA Genomics Software Solution for microRNA Research

Ultra-high-throughput genomic analysis platforms, such as the
SOLiD System, is changing the approach to genome-related research,
including small RNA discovery and detection and gene expression
profiling. InteRNA developed a bioinformatics solution,
miR-Intess(TM), that converts large sets of raw sequencing data into
interpretable formats, enabling researchers to integrate this
information with existing data resources.

InteRNA's miR-Intess is designed for the comprehensive analysis of
high-throughput small RNA sequencing data with the focus on discovery
and expression profiling of miRNAs and for the classification and
annotation of all sequencing reads according to current knowledge in
the small RNA field. Analysis includes alignment and annotation of
SOLiD System reads to a reference genome as well as the predication of
novel miRNA candidate genes.

"During a recent project, InteRNA was able to map and annotate 120
million SOLiD System reads of small RNAs onto a reference genome using
an open source alignment program, resulting in the identification of
novel microRNAs and the validation as well as digital expression
profiling of known microRNAs," said Dr. Edwin Cuppen, InteRNA
co-founder, a professor of genome biology at Utrecht University, and a
staff scientist at the Hubrecht Institute. "As researchers begin to
adapt microarray-based gene expression profiling to an
ultra-high-throughput platform, they will be evaluating how to manage
the significant increase in quantity and quality of data generated
from these platforms."

Biotique Software Translates High-Throughput Genomic Analysis Data

Biotique has commercially developed software, HT-BLIS
(High-Throughput HT-BLIS), which enables academic and research
organizations to process the massive amounts of data being generated
by high-throughput genomic analysis systems. HT-BLIS provides a
scalable informatics solution that is capable of receiving, storing,
and manipulating sequencing data in real time as it is generated by
genomic analysis platforms such as the SOLiD System.

"HT-BLIS software offers unprecedented resolution and speed to
gene expression, sequencing, and genotyping projects," said Stephen
Sanders, Biotique Systems' chief executive officer. "Our relationship
with Applied Biosystems is part of our commitment to providing
researchers with the informatics tools necessary to manage the
billions of bases per day generated by high-throughput genomic
analysis platforms."

The Software Development Community represents Applied Biosystems'
commitment to fostering innovation in life science technologies for
industry leading genetic analyzers, and real-time PCR sequence
detection systems.

"We have worked closely with companies that have developed
sophisticated software applications for scientists engaged with
high-throughput genomic analysis platforms," said Roger Canales,
senior manager of Applied Biosystems' SOLiD Software Development
Community. "As a result, Applied Biosystems has been able to clearly
define the requirements to help scientists be successful in conducting
their research projects."

Applied Biosystems is a global leader in the development and
commercialization of instrument-based systems, consumables, software,
and services for the life-science market and is a recognized market
leader in the commercialization of DNA sequencing platforms. The SOLiD
System, based on sequencing by oligonucleotide ligation and detection,
is Applied Biosystems' platform for ultra high-throughput genomic
analysis. Unlike polymerase sequencing approaches, the SOLiD System
utilizes a proprietary technology called stepwise ligation, which
generates high quality data for applications including, whole genome
sequencing, chromatin immunoprecipitation (ChIP), microbial and
eukaryotic resequencing, digital karyotyping, medical sequencing,
genotyping, gene expression, and small RNA discovery, among others.
For more information about the SOLiD System or the Software
Development Community please visit:
http://info.appliedbiosystems.com/solidsoftwarecommunity or
http://solidsoftwaretools.com

About Applied Biosystems Inc.

Applied Biosystems Inc. (formerly known as Applera Corporation) is
a global leader in the development and marketing of instrument-based
systems, consumables, software, and services for academic research,
the life science industry and commercial markets. Driven by its
employees' belief in the power of science to improve the human
condition, the company commercializes innovative technology solutions
for DNA, RNA, protein and small molecule analysis. Customers across
the disciplines of academic and clinical research, pharmaceutical
research and manufacturing, forensic DNA analysis, and agricultural
biotechnology use the company's tools and services to accelerate
scientific discovery, improve processes related to drug discovery and
development, detect potentially pathogenic microorganisms, and
identify individuals based on DNA sources. Applied Biosystems has a
comprehensive service and field applications support team for a global
installed base of high-performance genetic and protein analysis
solutions. On June 12, 2008, Applera Corporation and Invitrogen
Corporation (NASDAQ:IVGN) announced that their Boards of Directors had
approved a definitive merger agreement under which Invitrogen will
acquire all of the outstanding shares of Applied Biosystems stock. The
merger is subject to customary closing conditions and is targeted to
close in the fall of 2008. Further information regarding the merger
will be provided in a joint proxy statement/prospectus to be mailed to
stockholders of the company and Invitrogen. Investors and security
holders are urged to read this document when it becomes available
because it will contain important information. Applied Biosystems Inc.
is headquartered in Norwalk, CT, and reported sales of approximately
$2.1 billion during fiscal 2007. Information about Applied Biosystems,
including reports and other information filed by the company with the
Securities and Exchange Commission, is available at
http://www.appliedbiosystems.com. All information in this news release
is as of the date of the release, and Applied Biosystems does not
undertake any duty to update this information unless required by law.

About InteRNA Genomics B.V.

InteRNA Genomics B.V., a subsidiary of InteRNA Technologies B.V.
and based in Bilthoven, the Netherlands, offers services and software
for processing, analyzing and presenting ultra-high-throughput
sequencing data generated by various platforms. InteRNA's proprietary
informatics solutions, Intess(TM), convert large sets of raw
sequencing data into interpretable formats and integrate this
information with existing proprietary and public data resources.
InteRNA Genomics is co-founded by Dr. Eugene Berezikov and Dr. Edwin
Cuppen, leading scientists in U-HTP data generation and analysis.
Berezikov and Cuppen pioneered the application of high-throughput
sequencing technologies for expression profiling and discovery of
small RNAs and miRNAs in particular, as described in several
high-profile papers. For more information on InteRNA, please visit,
www.interna-genomics.com, or mail info@interna-genomics.com.

About Biotique Systems, Inc.

Biotique Systems is a privately held company that helps
pharmaceutical, agriculture and biotechnology companies increase
productivity by providing customizable, enterprise-wide solutions for
integrating, analyzing and sharing knowledge assets. By bringing
together people, projects, disparate data sources and workflow
applications Biotique Systems is helping leading companies such as
Bayer-Schering Pharma, Monsanto and Affymetrix integrate information
from discovery programs across disparate research disciplines and
geographic locations to facilitate innovation and discovery. Biotique
Systems is the premier provider of knowledge management and
integration solutions that focus on leveraging biological data and
Genomics to increase the productivity of drug, seed, and crop
development. For more information about Biotique Systems, call
775-787-9900, e-mail inquire@biotiquesystems.com, or visit
www.biotiquesystems.com.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking.
These may be identified by the use of forward-looking words or phrases
such as "should, "planned," and "expect," among others. These
forward-looking statements are based on our current expectations. The
Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for such forward-looking statements. In order to comply with
the terms of the safe harbor, we note that a variety of factors could
cause actual results and experience to differ materially from the
anticipated results or other expectations expressed in such
forward-looking statements. These factors include but are not limited
to: (1) rapidly changing technology and dependence on the development
and customer acceptance of new products; (2) sales dependent on
customers' capital spending policies and government-sponsored
research; and (3) other factors that might be described from time to
time in our filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and we do not undertake any duty to update this information, including
any forward-looking statements, unless required by law.

(C)Copyright 2008. Applied Biosystems Inc. All rights reserved.
Applera, Applied Biosystems, and AB (Design) are registered
trademarks, and SOLiD is a trademark of Applied Biosystems Inc. or its
subsidiaries in the U.S. and/or certain other countries.

SOURCE: Applied Biosystems Inc.

Applied Biosystems
Lauren Lum, 650-638-6916 (Media)
lauren.lum@appliedbiosystems.com
William Craumer, 650-638-6382 (Investors)
william.craumer@appliedbiosystems.com

Copyright Business Wire 2008